Arcutis Biotherapeutics Inc
ARQTHealthcare|Biotechnology|USA
$27.74
-1.03 (-3.58%)
Tangible Book
$1.40
About
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Stock Price
+81.7%(1Y)
Pipeline Summary
29 total trials6
Phase 1
14
Phase 2
10
Phase 3
1
Phase 4
Completed: 23Recruiting: 3NOT_YET_RECRUITING: 2Terminated: 1
Active Trials (3)
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
NCT07105254Non-segmental Vitiligo
Phase 2Recruiting
Enrollment: 20 participants
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
NCT07453602Atopic Dermatitis (AD)
Phase 1Recruiting
Enrollment: 125 participants
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
NCT07077902Hidradenitis Suppurativa
Phase 2Recruiting
Enrollment: 10 participants
BioScore
6.1/10
Watchlist
Ownership
Recent Insider Trades
Welgus Howard G.SELL
2026-06-174,731 shares @ $24.58
LIN SUE-JEANSELL
2026-06-154,946 shares @ $24.38
Vairavan LathaSELL
2026-05-11435 shares @ $21.05
Burnett PatrickSELL
2026-05-11222 shares @ $21.05
Vairavan LathaSELL
2026-05-041,341 shares @ $23.61
Recent News
2026-07-08 15:57:47
2026-07-08 12:30:39
2026-06-29 23:50:30
2026-06-18 02:03:27
Data last updated: Jul 12, 2026, 07:42 PM